Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination

Introduction. Immunotherapy based on dendritic cell vaccination has exciting perspectives for treatment of cancer. In order to clarify immunological mechanisms during vaccination it is essential with intensive monitoring of the responses. This may lead to optimization of treatment and prediction of responding patients. The aim of this study was to evaluate cytokine and biomarker responses in patients with colorectal cancer treated with a cancer vaccine based on dendritic cells pulsed with an allogeneic melanoma cell lysate. Material and methods. Plasma and serum samples were collected prior to vaccination and continuously during treatment. GM-CSF, IL-2, IL-6, TNF-α, IFN-γ, IL-4, IL-8, IL-1b, IL-5, IL-10, IL-12, MIP-1b, IP-10 and Eotaxin were analyzed in a multiplex assay with a Luminex 100™ instrument. CEA and TIMP-1 were analysed on ELISA platforms. Results. Patients achieving stable disease showed increasing levels of plasma GM-CSF, TNF-α, IFN-γ, IL-2, and IL-5. Patients with progressive disease showed significant increase in CEA and TIMP-1 levels, while patients with stable disease showed relatively unaltered levels. Conclusion. The increased levels of key pro-inflammatory cytokines in serum of patients who achieved stable disease following vaccination suggest the occurrence of vaccine-induced Th1 responses. Since Th1 responses seem to be essential in cancer immunotherapy this may indicate a therapeutic potential of the vaccine.

[1]  F. D. De Braud,et al.  First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer , 2007, Cancer.

[2]  J. Rosenberg,et al.  Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. , 2006, Journal of experimental & clinical cancer research : CR.

[3]  J. Kirkwood,et al.  Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma , 2002, The Journal of experimental medicine.

[4]  J. Rosenberg,et al.  Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. , 2008, Oncology reports.

[5]  R. Stenling,et al.  Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. , 2000, Anticancer research.

[6]  J. Xiang,et al.  CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes , 2007, Immunology.

[7]  P. Wadhwa,et al.  Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. , 2005, Journal of reproductive immunology.

[8]  F. Guadagni,et al.  Prognostic Value of Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Tumor Tissue Content in Colorectal Cancer , 2007, Oncology.

[9]  H. Nielsen,et al.  Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[10]  N. Brünner,et al.  Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment , 2008, Scandinavian journal of gastroenterology.

[11]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[12]  M. Goetz,et al.  Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. , 2007, Clinical colorectal cancer.

[13]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[14]  M. Kopf,et al.  Strong TCR Signaling, TLR Ligands, and Cytokine Redundancies Ensure Robust Development of Type 1 Effector T Cells1 , 2006, The Journal of Immunology.

[15]  Christoph H Emmerich,et al.  TRAIL signalling: decisions between life and death. , 2007, The international journal of biochemistry & cell biology.

[16]  H. Mellstedt,et al.  Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. Wolpin,et al.  Systemic treatment of colorectal cancer. , 2008, Gastroenterology.

[18]  Angus G. Dalgleish,et al.  Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy , 2002, Cancer Immunology, Immunotherapy.

[19]  A. Ohta,et al.  The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.

[20]  H. Nielsen,et al.  [Serological markers of colorectal cancer]. , 2005, Ugeskrift for laeger.

[21]  T. Morris,et al.  Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissuenhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase , 2001, British Journal of Cancer.

[22]  H. Nielsen,et al.  TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid , 2007, Clinical Cancer Research.

[23]  M. Duffy,et al.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.

[24]  N. Brünner,et al.  Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection , 2008, Scandinavian journal of gastroenterology.

[25]  Y. Collan,et al.  Prognostic significance of matrix metalloproteinases‐1, ‐2, ‐7 and ‐13 and tissue inhibitors of metalloproteinases‐1, ‐2, ‐3 and ‐4 in colorectal cancer , 2007, International journal of cancer.

[26]  H. Nielsen,et al.  Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[28]  L. Matrisian,et al.  Matrix metalloproteinases in colorectal cancer: Is it worth talking about? , 2004, Cancer and Metastasis Reviews.

[29]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Kummar,et al.  Advances in the Treatment of Metastatic Colorectal Cancer , 2009, American journal of therapeutics.

[31]  H. Nielsen,et al.  Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.

[32]  Ge Li,et al.  Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer , 2006, BMC Cancer.

[33]  P. Gibbs,et al.  Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres – what is current practice? , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[34]  E. Thiel,et al.  Immunological monitoring of cancer vaccine therapy , 2004, Expert opinion on biological therapy.

[35]  H. Nielsen,et al.  Localization of tissue inhibitor of metalloproteinases 1 (TIMP‐1) in human colorectal adenoma and adenocarcinoma , 2005, International journal of cancer.

[36]  Shung-Haur Yang,et al.  Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years , 2007, International Journal of Colorectal Disease.

[37]  E. Thiel,et al.  Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer , 2006, Clinical Cancer Research.

[38]  Paul Ziprin,et al.  Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. , 2009, Surgical oncology.

[39]  H. Shimada,et al.  Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer , 2008, Annals of Surgical Oncology.

[40]  Burkhard Becher,et al.  APC-derived cytokines and T cell polarization in autoimmune inflammation. , 2007, The Journal of clinical investigation.

[41]  P. Moingeon Strategies for designing vaccines eliciting Th1 responses in humans. , 2002, Journal of biotechnology.

[42]  K. Sasaki,et al.  Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. , 2007, Journal of experimental & clinical cancer research : CR.

[43]  M. Wallack,et al.  Immunotherapy in colorectal cancer. , 1981, Missouri medicine.

[44]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[45]  E. Hersh,et al.  Clinical applications of dendritic cell vaccination in the treatment of cancer , 2004, Cancer Immunology, Immunotherapy.

[46]  H. Brenner,et al.  Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. , 2006, European journal of cancer.